ME02331B - Derivati benzotiazola kao agensi protiv kancera - Google Patents
Derivati benzotiazola kao agensi protiv kanceraInfo
- Publication number
- ME02331B ME02331B MEP-2016-203A MEP20316A ME02331B ME 02331 B ME02331 B ME 02331B ME P20316 A MEP20316 A ME P20316A ME 02331 B ME02331 B ME 02331B
- Authority
- ME
- Montenegro
- Prior art keywords
- optionally
- compound according
- cyano
- group
- substituent
- Prior art date
Links
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000001424 substituent group Chemical group 0.000 claims 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 150000003839 salts Chemical group 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- GXLAKHKBZJXGHF-UHFFFAOYSA-N 2-chloro-n-[3-[[7-cyano-2-(cyclopropanecarbonylamino)-1,3-benzothiazol-6-yl]oxy]phenyl]-3-(2-cyanopropan-2-yl)benzamide Chemical compound N#CC(C)(C)C1=CC=CC(C(=O)NC=2C=C(OC=3C(=C4SC(NC(=O)C5CC5)=NC4=CC=3)C#N)C=CC=2)=C1Cl GXLAKHKBZJXGHF-UHFFFAOYSA-N 0.000 claims 2
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- LWHUINHGFIXZQT-UHFFFAOYSA-N n-[7-cyano-6-[3-[[2-[3-(trifluoromethyl)phenyl]acetyl]amino]phenoxy]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(CC(=O)NC=2C=C(OC=3C(=C4SC(NC(=O)C5CC5)=NC4=CC=3)C#N)C=CC=2)=C1 LWHUINHGFIXZQT-UHFFFAOYSA-N 0.000 claims 2
- ZLKPQAVVJKWQEL-UHFFFAOYSA-N n-[7-cyano-6-[3-[[6-(trifluoromethyl)pyridin-3-yl]carbamoylamino]phenoxy]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide Chemical compound C1=NC(C(F)(F)F)=CC=C1NC(=O)NC1=CC=CC(OC=2C(=C3SC(NC(=O)C4CC4)=NC3=CC=2)C#N)=C1 ZLKPQAVVJKWQEL-UHFFFAOYSA-N 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- YMMZSUHTTYMCQY-UHFFFAOYSA-N n-[7-cyano-6-[4-fluoro-3-[[4-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide Chemical compound C1=C(NC(=O)NC=2C=CC(=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 YMMZSUHTTYMCQY-UHFFFAOYSA-N 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (19)
1. Jedinjenje predstavljeno formulomnaznačeno time, štoR1 predstavlja neka C1-6 alkil grupa, koja opciono ima supstituent(e), neka C3-8 cikloalkil grupa, koja opciono ima supstituent(e), ili neka heterociklična grupa, koja opciono ima supstituent(e);X predstavlja -O- ili -NR2-, gde R2 predstavlja atom vodonika ili neka C1-6 alkil grupa;Y predstavljagde prsten A predstavlja benzenov prsten koji je opciono još supstituisan;Z predstavlja grupa, koja je(1) -NR3CO-,(2) -NR3CO-W1-,(3) -NR3CO-W1-O-,(4) -NR3CO-W1-O-W2-,(5) -NR3CO-W1-S-,(6) -NR3CO-W1-NR4-,(7) -NR3COO-,(8) -NR3CO-CO-,(9) -NR3CONR4-,(10) -NR3CONR4-W1-,(11) -NR3CONR4-W1-O-, ili(12) -CONR3-gde R3 i R4, svaki nezavisno, predstavlja atom vodonika ili neka C1-6 alkil grupa, a W1 i W2, svaki nezavisno, predstavlja neka C1-6 alkilen grupa, koja opciono ima supstituent(e), neka C2-6 alkenilen grupa, koja opciono ima supstituent(e), neka C2-6 alkinilen grupa, koja opciono ima supstituent(e), ili neka C3-6 cikloalkilen grupa, koja opciono ima supstituent(e);R5 predstavlja neka grupa 5- ili 6-članog prstena, koja opciono ima supstituent(e); iR6 predstavlja cijano grupa, ili neka njegova so.
2. Jedinjenje prema Zahtevu 1, naznačeno time, što R1 predstavlja (1) neka C1-6 alkil grupa, koja opciono ima supstituent(e), (2) neka C3-8 cikloalkil grupa, koja opciono ima supstituent(e), ili (3) meka 3- do 8-člana monociklična nearomatična heterociklična grupa, koja opciono ima supstituent(e), X predstavlja -O-, -NH- ili -N(CH3)-, Y predstavlja gde prsten A predstavlja benzenov prsten, koji opciono ima 1 do 3 supstituenta koji se biraju između (1) C1-6 alkil, i (2) atom halogena, Z predstavlja (1) -NR3CO-, (2) -NR3CO-W1-, (3) -NR3CONR4-, ili (4) -CONR3- gde je svaki od simbola definisan u Zahtevu 1, i R5 predstavlja (1) fenil, koji opciono ima supstituent(e), ili (2) neka 5- ili 6-člana monociklična aromatična heterocikličnaa grupa, koja opciono ima supstituent(e).
3. Jedinjenje prema Zahtevu 2, naznačeno time, što R1 predstavlja (1) neka C1-6 alkil grupa, koja opciono ima jednu 3- do 8-članu monocikličnu nearomatičnu heterocikličnu grupu, koja opciono ima 1 do 3 C1-6 alkil grupe, ili (2) neka C3-8 cikloalkil grupa.
4. Jedinjenje prema Zahtevu 2, naznačeno time, što X predstavlja -O-.
5. Jedinjenje prema Zahtevu 2, naznačeno time, što Y predstavlja gde je prsten A benzenov prsten, koji opciono ima 1 do 3 supstituenta koji se biraju između (1) C1-6 alkil, i (2) atom halogena.
6. Jedinjenje prema Zahtevu 2, naznačeno time, što Z predstavlja (1) -NHCO-, (2) -NHCO-W1b, gde je W1b neka C1-6 alkilen grupa, (3) -NHCONH-, ili (4) -CONH-.
7. Jedinjenje prema Zahtevu 2, naznačeno time, što R5 predstavlja (1) fenil koji opciono ima 1 do 3 supstituenta koji se biraju između (a) atom halogena, (b) neki C1-6 alkil, koji opciono ima 1 do 3 supstituenta koji se biraju između (i) atom halogena, i (ii) cijano, (c) neki C1-6 alkoksi, koji opciono ima 1 do 3 supstituenta koji se biraju između (i) atom halogena, i (ii) cijano, (d) C3-8 cikloalkil, koji opciono ima 1 do 3 cijano, i (e) C2-6 alkinil, ili (2) neka 5- ili 6-člana monociklična aromatična heterocikličnaa grupa, koja opciono ima 1 do 3 supstituenta koji se biraju između (a) atom halogena, (b) C1-6 alkil, koji opciono ima 1 do 3 halogena atoma, (c) C3-8 cikloalkil, i (d) fenil.
8. Jedinjenje prema Zahtevu 1, koje predstavlja 2-hloro-N-[3-({7-cijano-2-[(ciklopropilkarbonil)amino]-1,3-benzotiazol-6-il}oksi)fenil]-3-(1-cijano-1-metiletil)benzamid, ili neka njegova so.
9. Jedinjenje prema Zahtevu 1, koje predstavlja 2-hloro-N-[3-({7-cijano-2-[(ciklopropilkarbonil)amino]-1,3-benzotiazol-6-il}oksi)fenil]-3-(1-cijano-1-metiletil)benzamid.
10. Jedinjenje prema Zahtevu 1, koje predstavlja N-{7-cijano-6-[4-fluoro-3-({[4-(trifluorometil)fenil]karbamoil}amino)fenoksi]-1,3-benzotiazol-2-il}ciklopropankarboksamid, ili neka njegova so.
11. Jedinjenje prema Zahtevu 1 koje predstavlja N-{7-cijano-6-[4-fluoro-3-({[4-(trifluorometil)fenil]karbamoil}amino)fenoksi]-1,3-benzotiazol-2-il}ciklopropankarboksamid.
12. Jedinjenje prema Zahtevu 1 koje predstavlja N-{7-cijano-6-[3-({[3-(trifluorometil)fenil]acetil}amino)fenoksi]-1,3-benzotiazol-2-il}ciklopropankarboksamid, ili neka njegova so.
13. Jedinjenje prema Zahtevu 1 koje predstavlja N-{7-cijano-6-[3-({[3-(trifluorometil)fenil]acetil}amino)fenoksi]-1,3-benzotiazol-2-il}ciklopropankarboksamid.
14. Jedinjenje prema Zahtevu 1 koje predstavlja N-{7-cijano-6-[3-({[6-(trifluorometil)piridin-3-il]karbamoil}amino)fenoksi]-1,3-benzotiazol-2-il}ciklopropankarboksamid, ili neka njegova so.
15. Jedinjenje prema Zahtevu 1 koje predstavlja N-{7-cijano-6-[3-({[6-(trifluorometil)piridin-3-il]karbamoil}amino)fenoksi]-1,3-benzotiazol-2-il}ciklopropankarboksamid.
16. Jedinjenje prema Zahtevu 1 koje predstavlja N-{7-cijano-6-[4-fluoro-3-({[3-(trifluorometil)fenil]acetil}amino)fenoksi]-1,3-benzotiazol-2-il}ciklopropankarboksamid, ili neka njegova so.
17. Jedinjenje prema Zahtevu 1 koje predstavlja N-{7-cijano-6-[4-fluoro-3-({[3-(trifluorometil)fenil]acetil}amino)fenoksi]-1,3-benzotiazol-2-il}ciklopropankarboksamid.
18. Medikament koji sadrži jedinjenje prema Zahtevu 1.
19. Upotreba jedinjenja prema Zahtevu 1 za tretman ili profilaksu kancera.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008307581 | 2008-12-02 | ||
| JP2009125256 | 2009-05-25 | ||
| PCT/JP2009/070447 WO2010064722A1 (en) | 2008-12-02 | 2009-12-01 | Benzothiazole derivatives as anticancer agents |
| EP09775337.0A EP2358689B9 (en) | 2008-12-02 | 2009-12-01 | Benzothiazole derivatives as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02331B true ME02331B (me) | 2016-04-28 |
Family
ID=42026212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-203A ME02331B (me) | 2008-12-02 | 2009-12-01 | Derivati benzotiazola kao agensi protiv kancera |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US8143258B2 (me) |
| EP (1) | EP2358689B9 (me) |
| JP (1) | JP5640014B2 (me) |
| KR (1) | KR101639092B1 (me) |
| CN (1) | CN102300854B (me) |
| AR (1) | AR074435A1 (me) |
| AU (1) | AU2009323274B2 (me) |
| BR (1) | BRPI0922109A2 (me) |
| CA (1) | CA2745144C (me) |
| CL (1) | CL2011001299A1 (me) |
| CO (1) | CO6400140A2 (me) |
| CR (1) | CR20110366A (me) |
| CY (1) | CY1117178T1 (me) |
| DK (1) | DK2358689T5 (me) |
| DO (1) | DOP2011000165A (me) |
| EA (1) | EA019447B1 (me) |
| EC (1) | ECSP11011165A (me) |
| ES (1) | ES2557304T3 (me) |
| GE (1) | GEP20146003B (me) |
| HR (1) | HRP20151370T1 (me) |
| HU (1) | HUE026491T4 (me) |
| IL (1) | IL213184A0 (me) |
| JO (1) | JO3101B1 (me) |
| MA (1) | MA32911B1 (me) |
| ME (1) | ME02331B (me) |
| MX (1) | MX2011005836A (me) |
| MY (1) | MY150989A (me) |
| NZ (1) | NZ593759A (me) |
| PE (1) | PE20110588A1 (me) |
| PL (1) | PL2358689T3 (me) |
| PT (1) | PT2358689E (me) |
| RS (1) | RS54370B9 (me) |
| SG (1) | SG171426A1 (me) |
| SI (1) | SI2358689T1 (me) |
| SM (1) | SMT201500316B (me) |
| TN (1) | TN2011000280A1 (me) |
| TW (1) | TWI436987B (me) |
| UY (1) | UY32281A (me) |
| WO (1) | WO2010064722A1 (me) |
| ZA (1) | ZA201104659B (me) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200904816A (en) * | 2007-06-05 | 2009-02-01 | Takeda Pharmaceutical | Fused heterocycle derivatives and use thereof |
| US8324395B2 (en) * | 2007-08-23 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US8445509B2 (en) | 2008-05-08 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
| US8697874B2 (en) | 2008-12-01 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US9725427B2 (en) | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
| CN104428001A (zh) * | 2012-03-30 | 2015-03-18 | 武田药品工业有限公司 | Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与 |
| CA3139033A1 (en) | 2012-08-22 | 2014-02-27 | Cornell University | Methods for inhibiting fascin |
| PT3013798T (pt) | 2013-06-28 | 2018-11-12 | Beigene Ltd | Compostos de ureia tricíclicos fusionados como inibidores de raf quinase e/ou dímeros de raf quinase |
| US9670231B2 (en) | 2013-06-28 | 2017-06-06 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| CN103435573B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 苄基取代的噻唑并环己烷类化合物、其制备方法和用途 |
| CN103408541B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途 |
| CN103435572B (zh) * | 2013-07-16 | 2015-02-04 | 浙江医药高等专科学校 | 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途 |
| CN103382190B (zh) * | 2013-07-16 | 2015-01-14 | 浙江医药高等专科学校 | 一类噻唑并环己烷类化合物、其制备方法和用途 |
| CA3195815A1 (en) | 2014-02-20 | 2015-08-27 | Cornell University | Compounds and methods for inhibiting fascin |
| WO2016008048A1 (en) | 2014-07-15 | 2016-01-21 | Ontario Institute For Cancer Research | Methods and devices for predicting anthracycline treatment efficacy |
| US20190117652A1 (en) * | 2014-12-23 | 2019-04-25 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and taxanes |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| WO2017165491A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| CN109053630B (zh) * | 2018-08-22 | 2022-04-01 | 中国人民解放军第二军医大学 | 一种苯并噻唑类衍生物及其用途 |
| US12509455B2 (en) | 2018-11-07 | 2025-12-30 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof |
| EP3876930A4 (en) | 2018-11-07 | 2022-07-20 | Dana-Farber Cancer Institute, Inc. | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| EP3876939A4 (en) * | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020232445A1 (en) * | 2019-05-16 | 2020-11-19 | The Regents Of The University Of California | Modulators of pyrimidine nucleotide biosynthetic pathways |
| CN115996917B (zh) | 2020-05-06 | 2025-10-28 | 艾捷斯治疗公司 | 作为jak2抑制剂的6-杂芳基氧基苯并咪唑和氮杂苯并咪唑 |
| CN112094248B (zh) * | 2020-09-17 | 2023-05-12 | 中国人民解放军海军军医大学 | 一种取代苯并噻唑类化合物及其用途 |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| TW202325289A (zh) | 2021-11-09 | 2023-07-01 | 美商雅捷可斯治療公司 | Ｊａｋ２抑制劑之形式及組合物 |
| EP4430042A1 (en) | 2021-11-09 | 2024-09-18 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CN115724837B (zh) * | 2022-10-26 | 2024-07-23 | 中国人民解放军海军军医大学 | 一种抑制程序性细胞坏死的苯并噻唑衍生物及其应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2399026A (en) * | 1941-02-06 | 1946-04-23 | Chem Ind Basel | Amides of 2-aminoarylenethiazoles |
| US4096264A (en) | 1975-12-09 | 1978-06-20 | Merck & Co., Inc. | Certain substituted imidazo [1,2-a] pyridines |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| IL158649A0 (en) | 1997-09-26 | 2004-05-12 | Zentaris Gmbh | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
| WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| DZ3004A1 (fr) * | 1999-01-13 | 2004-03-27 | Bayer Corp | Omega-carboxyaryl diphényl urées substitués comme inhibiteurs de raf kinase. |
| HK1042251B (en) | 1999-01-13 | 2012-07-20 | Bayer Healthcare Llc | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PL204856B1 (pl) * | 1999-01-22 | 2010-02-26 | Kirin Pharma Kk | Pochodne chinoliny lub chinazoliny, jej zastosowanie i kompozycja farmaceutyczna |
| AU5570600A (en) | 1999-07-01 | 2001-01-22 | Ajinomoto Co., Inc. | Heterocyclic compounds and medicinal use thereof |
| PL203782B1 (pl) | 1999-11-05 | 2009-11-30 | Astrazeneca Ab | Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania |
| WO2001057008A1 (en) | 2000-02-07 | 2001-08-09 | Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| SK287142B6 (sk) | 2000-02-15 | 2010-01-07 | Sugen, Inc. | Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie |
| GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
| ES2218391T3 (es) | 2000-03-06 | 2004-11-16 | Smithkline Beecham Plc | Derivados de imidazol como inhibidores de raf-cinasa. |
| KR100526487B1 (ko) | 2000-06-21 | 2005-11-08 | 에프. 호프만-라 로슈 아게 | 벤조티아졸 유도체 |
| KR20030030027A (ko) | 2000-09-21 | 2003-04-16 | 스미스클라인비이참피이엘시이 | Ｒａｆ 키나제 저해제인 이미다졸 유도체 |
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| JP2004517080A (ja) * | 2000-11-29 | 2004-06-10 | グラクソ グループ リミテッド | Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体 |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| US20040192689A1 (en) | 2001-09-05 | 2004-09-30 | Dean David Kenneth | Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| GB0121488D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| WO2003022838A1 (en) | 2001-09-05 | 2003-03-20 | Smithkline Beecham Plc | Pyridine substituted furan derivatives as raf kinase inhibitors |
| EP1487824B1 (en) | 2002-03-01 | 2007-06-20 | SmithKline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
| EA007987B1 (ru) | 2002-03-29 | 2007-02-27 | Чирон Корпорейшн | Замещённые бензазолы и их применение в качестве ингибиторов киназы raf |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| EP2258365B1 (en) | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
| US7378233B2 (en) * | 2003-04-12 | 2008-05-27 | The Johns Hopkins University | BRAF mutation T1796A in thyroid cancers |
| DE10334663A1 (de) * | 2003-07-30 | 2005-03-10 | Merck Patent Gmbh | Harnstoffderivate |
| DE10337942A1 (de) | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| CA2542653A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | Substituted benzazoles and use thereof as inhibitors of raf kinase |
| AU2005244736B2 (en) | 2004-05-07 | 2012-06-28 | Exelixis Patent Company Llc | Raf modulators and methods of use |
| MX2007001155A (es) | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| KR20060079098A (ko) | 2004-12-31 | 2006-07-05 | 주식회사 엘지생명과학 | 신규한([1,3]티아졸로[5,4-ｂ]피리딘-2-일)-2-카르복사마이드유도체 |
| WO2006076376A1 (en) | 2005-01-11 | 2006-07-20 | Medicinova, Inc. | Topical treatment of solid tumors and ocular neovascularization |
| CN101106990B (zh) * | 2005-01-26 | 2010-12-08 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| US7514439B2 (en) | 2005-07-11 | 2009-04-07 | Mitsubishi Tanabe Pharma Corporation | Oxime derivative and preparations thereof |
| TW200804345A (en) | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| KR20070052207A (ko) | 2005-11-16 | 2007-05-21 | 주식회사 엘지생명과학 | 신규한 ｋｄｒ 억제제 |
| AU2007237904B2 (en) | 2006-04-19 | 2011-03-03 | Novartis Ag | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
| AR062207A1 (es) | 2006-08-04 | 2008-10-22 | Takeda Pharmaceutical | Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer. |
| EP2058309A4 (en) | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| JP4328820B2 (ja) | 2007-01-10 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2008084873A1 (ja) | 2007-01-10 | 2008-07-17 | Mitsubishi Tanabe Pharma Corporation | オキシム誘導体 |
| CN101260106A (zh) * | 2007-03-06 | 2008-09-10 | 中国药科大学 | Raf激酶抑制剂及其制备方法和用途 |
| US20100203043A1 (en) | 2007-04-13 | 2010-08-12 | Ree Anne H | Treatment and diagnosis of metastatic prostate cancer with inhibitors of epidermal growth factor receptor (egfr) |
| WO2008141275A1 (en) | 2007-05-11 | 2008-11-20 | The Johns Hopkins University | Biomarkers for melanoma |
| JP2010528032A (ja) | 2007-05-23 | 2010-08-19 | ノバルティス アーゲー | 甲状腺癌の処置のためのｒａｆ阻害剤 |
| TW200904816A (en) | 2007-06-05 | 2009-02-01 | Takeda Pharmaceutical | Fused heterocycle derivatives and use thereof |
| JP2008307581A (ja) | 2007-06-15 | 2008-12-25 | Sanyo Special Steel Co Ltd | 管材の洗浄装置 |
| US8324395B2 (en) | 2007-08-23 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JP5350247B2 (ja) | 2007-08-29 | 2013-11-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2009028655A1 (ja) | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
| JP2009125256A (ja) | 2007-11-22 | 2009-06-11 | Kandado:Kk | 安眠枕 |
| CN101220024A (zh) * | 2007-12-11 | 2008-07-16 | 杜晓敏 | 一组抑制激酶的抗癌化合物 |
| US20110081362A1 (en) | 2008-01-31 | 2011-04-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| US20090275546A1 (en) * | 2008-04-10 | 2009-11-05 | Istituto Superiore Di Sanita | Diagnostic tests and personalized treatment regimes for cancer stem cells |
| US8445509B2 (en) | 2008-05-08 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
-
2009
- 2009-11-25 JO JOP/2009/0448A patent/JO3101B1/ar active
- 2009-12-01 BR BRPI0922109-3A patent/BRPI0922109A2/pt not_active IP Right Cessation
- 2009-12-01 NZ NZ593759A patent/NZ593759A/en not_active IP Right Cessation
- 2009-12-01 JP JP2011538209A patent/JP5640014B2/ja not_active Expired - Fee Related
- 2009-12-01 UY UY0001032281A patent/UY32281A/es not_active Application Discontinuation
- 2009-12-01 MX MX2011005836A patent/MX2011005836A/es active IP Right Grant
- 2009-12-01 SI SI200931334T patent/SI2358689T1/sl unknown
- 2009-12-01 WO PCT/JP2009/070447 patent/WO2010064722A1/en not_active Ceased
- 2009-12-01 AR ARP090104620A patent/AR074435A1/es active IP Right Grant
- 2009-12-01 ME MEP-2016-203A patent/ME02331B/me unknown
- 2009-12-01 EA EA201170735A patent/EA019447B1/ru not_active IP Right Cessation
- 2009-12-01 US US12/628,697 patent/US8143258B2/en not_active Expired - Fee Related
- 2009-12-01 DK DK09775337.0T patent/DK2358689T5/en active
- 2009-12-01 RS RS20150768A patent/RS54370B9/sr unknown
- 2009-12-01 PL PL09775337T patent/PL2358689T3/pl unknown
- 2009-12-01 CA CA2745144A patent/CA2745144C/en active Active
- 2009-12-01 KR KR1020117015343A patent/KR101639092B1/ko not_active Expired - Fee Related
- 2009-12-01 GE GEAP200912278A patent/GEP20146003B/en unknown
- 2009-12-01 HR HRP20151370TT patent/HRP20151370T1/hr unknown
- 2009-12-01 CN CN200980155786.1A patent/CN102300854B/zh not_active Expired - Fee Related
- 2009-12-01 PE PE2011001128A patent/PE20110588A1/es active IP Right Grant
- 2009-12-01 PT PT97753370T patent/PT2358689E/pt unknown
- 2009-12-01 AU AU2009323274A patent/AU2009323274B2/en not_active Ceased
- 2009-12-01 TW TW098140940A patent/TWI436987B/zh not_active IP Right Cessation
- 2009-12-01 HU HUE09775337A patent/HUE026491T4/en unknown
- 2009-12-01 MY MYPI20112494 patent/MY150989A/en unknown
- 2009-12-01 ES ES09775337.0T patent/ES2557304T3/es active Active
- 2009-12-01 EP EP09775337.0A patent/EP2358689B9/en active Active
- 2009-12-01 SG SG2011038247A patent/SG171426A1/en unknown
-
2011
- 2011-05-26 IL IL213184A patent/IL213184A0/en active IP Right Grant
- 2011-05-30 TN TN2011000280A patent/TN2011000280A1/fr unknown
- 2011-06-01 DO DO2011000165A patent/DOP2011000165A/es unknown
- 2011-06-01 CL CL2011001299A patent/CL2011001299A1/es unknown
- 2011-06-23 ZA ZA2011/04659A patent/ZA201104659B/en unknown
- 2011-06-24 CR CR20110366A patent/CR20110366A/es unknown
- 2011-06-29 EC EC2011011165A patent/ECSP11011165A/es unknown
- 2011-06-30 CO CO11082152A patent/CO6400140A2/es active IP Right Grant
- 2011-06-30 MA MA33985A patent/MA32911B1/fr unknown
-
2012
- 2012-01-10 US US13/347,302 patent/US8497274B2/en not_active Expired - Fee Related
-
2015
- 2015-12-15 SM SM201500316T patent/SMT201500316B/it unknown
- 2015-12-17 CY CY20151101155T patent/CY1117178T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02331B (me) | Derivati benzotiazola kao agensi protiv kancera | |
| JP2012510467A5 (me) | ||
| RU2348617C2 (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| MY142807A (en) | Benzimidazole derivative and use thereof. | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| NO20064133L (no) | 5,6-dialkyl-7-amino-triazolpyrimidiner, fremgangsmate for fremstilling- av dem, deres anvendelse for a bekjempe skadelig sopp, og midler som inneholder disse forbindelsene | |
| ATE377007T1 (de) | Thiazol- und oxazolderivate, die sich für die behandlung von herzkreislauferkrankungen und ähnlichen erkrankungen eignen | |
| ME02696B (me) | MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI | |
| RU2013114351A (ru) | Пестицидные композиции | |
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| NO20090595L (no) | Ny pyridazinforbindelse og anvendelse derav | |
| JP2017507122A5 (me) | ||
| ME02766B (me) | Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene | |
| JP2019506430A5 (me) | ||
| RU2007139453A (ru) | Гетеробициклические ингибиторы вируса гепатита с (hcv) | |
| MY140070A (en) | 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
| JP2011529964A5 (me) | ||
| EA200970598A1 (ru) | Замещенные производные гетероарилпиридопиримидона | |
| MX344276B (es) | Compuesto de piperidina novedoso o sal del mismo. | |
| JP2013542980A5 (me) | ||
| JP2016503403A5 (me) | ||
| CN110225781A (zh) | 噻唑衍生物及其应用 | |
| RU2016151688A (ru) | Аминоиндановые соединения и их применение при лечении боли | |
| JP2018527324A5 (me) | ||
| AR082534A1 (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes |